The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications, accelerating early discovery innovation into the clinic.
This forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising.
If you are part of a research team that is looking to accelerate the approval of cell engager therapies, then this conference has been curated with you in mind.
Below are a few highlights you won’t want to miss:
- Drive efficacy in solid tumors with solid tumor targets addressed by Roche, Amgen, Pfizer, Merus, andCompass Therapeutics
- Modulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor, Harbour Biomed, Crescendo Biologics, Pieres,and Aptevo
- Harness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck, Lava Therapeutics, Verseau Tx, andoNKo-Innate
- Improving the therapeutic window of cell engagers – addressing toxicity, half-life, and CRS withAmunix, Synaffix, Revitope, and TeneoBio
To know more about 3rd Cell Engager Summit please click here.